|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
IL101728A
(en)
|
1991-05-03 |
2007-08-19 |
Univ Yale |
Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
|
|
US5786158A
(en)
|
1992-04-30 |
1998-07-28 |
Yale University |
Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
|
|
US20050112121A1
(en)
|
1992-04-30 |
2005-05-26 |
Yale University |
Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
|
|
US5840299A
(en)
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
DK0861261T3
(da)
|
1995-06-28 |
2009-12-14 |
Imp Cancer Res Tech |
Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
|
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
|
JPH09124697A
(ja)
|
1995-11-01 |
1997-05-13 |
Toagosei Co Ltd |
ペプチド及びモノクローナル抗体
|
|
EP0861894B1
(en)
|
1995-11-17 |
2006-03-08 |
Asahi Kasei Kabushiki Kaisha |
Differentiation-suppressive polypeptide
|
|
US20020137890A1
(en)
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20030180784A1
(en)
|
1997-04-04 |
2003-09-25 |
Millennium Pharmaceuticals, Inc. |
Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
|
|
AU6952498A
(en)
|
1997-04-04 |
1998-10-30 |
Millenium Pharmaceuticals, Inc. |
Novel human delta3 compositions and therapeutic and diagnostic uses therefor
|
|
US20060122373A1
(en)
|
1997-04-04 |
2006-06-08 |
Millennium Pharmaceuticals, Inc. |
Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
|
|
US6121045A
(en)
|
1997-04-04 |
2000-09-19 |
Millennium Biotherapeutics, Inc. |
Human Delta3 nucleic acid molecules
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4171528B2
(ja)
|
1997-05-14 |
2008-10-22 |
旭化成株式会社 |
新規な分化抑制剤
|
|
AU8162898A
(en)
|
1997-06-18 |
1999-01-04 |
Trustees Of Columbia University In The City Of New York, The |
Angiogenic modulation by notch signal transduction
|
|
US6004528A
(en)
|
1997-09-18 |
1999-12-21 |
Bergstein; Ivan |
Methods of cancer diagnosis and therapy targeted against the cancer stemline
|
|
CA2337492A1
(en)
|
1998-07-27 |
2000-02-10 |
Amgen Inc. |
Delta-related polypeptides
|
|
EP1179541B1
(en)
|
1999-04-28 |
2004-06-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting VEGF
|
|
CA2391455A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20110131679A2
(en)
|
2000-04-19 |
2011-06-02 |
Thomas La Rosa |
Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
|
|
US20020028488A1
(en)
|
2000-06-19 |
2002-03-07 |
Sujay Singh |
Transgenic avian species for making human and chimeric antibodies
|
|
US20050089518A1
(en)
|
2001-12-07 |
2005-04-28 |
Clarke Michael F. |
Prospective identification and characterization of breast cancer stem cells
|
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
|
US6689744B2
(en)
|
2000-09-22 |
2004-02-10 |
Genentech, Inc. |
Notch receptor agonists and uses
|
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
|
EP1410018A1
(en)
|
2001-07-25 |
2004-04-21 |
Lorantis Limited |
Method for detecting modultators of notch signalling
|
|
AU2002317333C1
(en)
|
2001-08-01 |
2009-06-25 |
University Of Bristol |
VEGF isoform
|
|
EP1446424A2
(en)
|
2001-11-14 |
2004-08-18 |
Lorantis Limited |
Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system
|
|
JP2005526701A
(ja)
|
2001-11-14 |
2005-09-08 |
ロランティス リミテッド |
内科療法
|
|
US20050137130A1
(en)
|
2001-11-14 |
2005-06-23 |
Bodmer Mark W. |
Medical treatment
|
|
AUPS054702A0
(en)
*
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
GB0218879D0
(en)
|
2002-08-14 |
2002-09-25 |
Lorantis Ltd |
Medical treatment
|
|
EP1537145A1
(en)
|
2002-09-10 |
2005-06-08 |
Lorantis Limited |
Pharmaceutical compositions and medical treatments comprising notch ligand proteins
|
|
CA2519875C
(en)
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
CA2534898A1
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
FR2859725B1
(fr)
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
|
EP2583685A1
(en)
|
2004-06-10 |
2013-04-24 |
Regeneron Pharmaceuticals, Inc. |
Method of administering and using VEGF inhibitors for the treatment of human cancer
|
|
ES2421556T3
(es)
|
2004-06-15 |
2013-09-03 |
Hoffmann La Roche |
Utilización de hormonas cardíacas para diagnosticar el riesgo de sufrir complicaciones cardiovasculares como consecuencia de medicamentos cardiotóxicos
|
|
EP1755645A2
(en)
|
2004-06-18 |
2007-02-28 |
Regeneron Pharmaceuticals, Inc. |
Vegf inhibitors for the treatment of malignant pleural effusion
|
|
EP1615036B1
(en)
|
2004-07-07 |
2007-09-19 |
F.Hoffmann-La Roche Ag |
Multimarker panel for diabetes type 1 and 2
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US20080254031A1
(en)
|
2004-09-09 |
2008-10-16 |
Exonhit Therapeutics Sa |
Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
|
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ４抗体
|
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
|
US20060134121A1
(en)
|
2004-10-29 |
2006-06-22 |
Gavin Thurston |
DII4 antagonists, assays, and therapeutic methods thereof
|
|
JP2008519829A
(ja)
|
2004-11-10 |
2008-06-12 |
ヒュブレヒト ラボラトリウム |
Ｎｏｔｃｈ経路活性化の阻害による腸腺腫および／または腺癌の処置
|
|
EP1812064A4
(en)
|
2004-11-19 |
2009-07-08 |
Cornell Res Foundation Inc |
USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY
|
|
US7432107B2
(en)
|
2005-01-24 |
2008-10-07 |
Roche Diagnostics Operations, Inc. |
Cardiac hormones for assessing cardiovascular risk
|
|
EP1853298A2
(en)
|
2005-02-11 |
2007-11-14 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス，インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
EP3530736A3
(en)
*
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
RU2007146986A
(ru)
|
2005-06-02 |
2009-06-27 |
ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) |
Способы лечения опухолей головного мозга с использованием антител
|
|
KR101704734B1
(ko)
*
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
AU2006279658A1
(en)
|
2005-08-12 |
2007-02-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of diseases by subcutaneous administration of a VEGF antagonist
|
|
EP1928486A2
(en)
|
2005-09-01 |
2008-06-11 |
Vasgene Therapeutics, Inc. |
Methods for using and identifying modulators of delta-like 4
|
|
US7906116B2
(en)
|
2005-09-01 |
2011-03-15 |
Parkash Gill |
Methods for using and identifying modulators of Delta-like 4
|
|
EP1945754B1
(en)
|
2005-10-31 |
2014-07-23 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
PL1962895T3
(pl)
|
2005-12-16 |
2013-06-28 |
Regeneron Pharma |
Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
|
|
CA2642685A1
(en)
|
2006-02-17 |
2007-08-30 |
Gilead Colorado, Inc. |
Antihypertensive therapy
|
|
WO2007103114A2
(en)
|
2006-03-07 |
2007-09-13 |
The Brigham & Women's Hospital, Inc. |
Notch inhibition in the treatment or prevention of atherosclerosis
|
|
US7354582B2
(en)
|
2006-03-10 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF antagonists for the treatment of malignant gliomas
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
JP2009539870A
(ja)
|
2006-06-06 |
2009-11-19 |
ジェネンテック・インコーポレーテッド |
血管発生の調節ための組成物および方法
|
|
AU2007319672B2
(en)
|
2006-06-06 |
2011-06-30 |
Genentech, Inc. |
Anti-DLL4 antibodies and methods using same
|
|
US7919092B2
(en)
|
2006-06-13 |
2011-04-05 |
Oncomed Pharmaceuticals, Inc. |
Antibodies to notch receptors
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
NZ574794A
(en)
|
2006-08-07 |
2011-06-30 |
Regeneron Pharma |
Use of delta-like ligand 4 (DLL4) antagonists for treating eye vascular and ischemic injury
|
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
HRP20160082T1
(hr)
|
2006-09-29 |
2016-02-26 |
Oncomed Pharmaceuticals, Inc. |
Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
|
|
CN101583624B
(zh)
*
|
2006-09-29 |
2012-11-21 |
昂考梅德药品有限公司 |
用于诊断和治疗癌症的组合物及其用途
|
|
CA2666974A1
(en)
|
2006-10-20 |
2008-11-06 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
US8466154B2
(en)
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
|
US20100166746A1
(en)
|
2006-12-04 |
2010-07-01 |
Medlmmune Way |
High potency recombinant antibodies, methods for producing them and use in cancer therapy
|
|
JP2010512407A
(ja)
|
2006-12-11 |
2010-04-22 |
ジェネンテック インコーポレイテッド |
新生物を処置するための組成物および方法
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
US20080248033A1
(en)
|
2006-12-19 |
2008-10-09 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
|
EP2120996A2
(en)
|
2006-12-20 |
2009-11-25 |
Vasgene Therapeutics, Inc. |
Methods for using and identifying modulators of delta-like 4
|
|
EP2125013A4
(en)
|
2007-01-26 |
2010-04-07 |
Bioinvent Int Ab |
DLL4 SIGNALING INHIBITOR AND ITS USES
|
|
WO2008137318A1
(en)
|
2007-05-04 |
2008-11-13 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating disorders associated with salt or fluid retention
|
|
GB0709333D0
(en)
|
2007-05-15 |
2007-06-20 |
Smart Targeting Ltd |
Binding protein
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
AU2008315414A1
(en)
|
2007-10-25 |
2009-04-30 |
Philogene, Inc. |
Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF)
|
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗－ｖｅｇｆ抗體
|
|
WO2009075565A1
(en)
|
2007-12-12 |
2009-06-18 |
Erasmus University Medical Center Rotterdam |
Methods for controlling vasculogenesis
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CN102112490B
(zh)
*
|
2008-07-08 |
2014-10-22 |
昂考梅德药品有限公司 |
Notch1受体结合剂和其使用方法
|
|
JP5606438B2
(ja)
|
2008-07-23 |
2014-10-15 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗血管新生療法を受容可能な被験体の同定
|
|
JP2011528798A
(ja)
|
2008-07-23 |
2011-11-24 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗血管形成療法のモニター
|
|
WO2010098788A2
(en)
*
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
|
US9221902B2
(en)
|
2008-11-07 |
2015-12-29 |
Fabrus, Inc. |
Combinatorial antibody libraries and uses thereof
|
|
UY32317A
(es)
|
2008-12-12 |
2010-07-30 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
AR076344A1
(es)
|
2009-04-20 |
2011-06-01 |
Genentech Inc |
Metodo de terapia complementaria contra el cancer
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
|
|
CA2766166A1
(en)
|
2009-07-08 |
2011-01-13 |
Amgen Inc. |
Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
|
|
CA2771575A1
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
UY32920A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
JP2013508308A
(ja)
|
2009-10-23 |
2013-03-07 |
ガーバン インスティテュート オブ メディカル リサーチ |
修飾可変ドメイン分子、ならびにその産生および使用方法
|
|
EP2493497A4
(en)
|
2009-11-01 |
2013-07-24 |
Brigham & Womens Hospital |
NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
|
|
US20110165162A1
(en)
|
2009-12-01 |
2011-07-07 |
Oncomed Pharmaceuticals, Inc. |
Methods for Treating Cancers Comprising K-ras Mutations
|
|
MX2012008085A
(es)
*
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
|
JO3183B1
(ar)
|
2010-01-29 |
2018-03-08 |
Regeneron Pharma |
طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
|
|
KR20120117931A
(ko)
|
2010-02-12 |
2012-10-24 |
온코메드 파마슈티칼스, 인크. |
폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
|
|
WO2011109298A2
(en)
|
2010-03-02 |
2011-09-09 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
LT2609118T
(lt)
|
2010-08-23 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antikūnai ir jų panaudojimo būdai
|
|
US8551479B2
(en)
*
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
US20130323265A1
(en)
|
2010-11-15 |
2013-12-05 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating cancer with dll4 antagonists
|
|
WO2012073987A1
(ja)
*
|
2010-12-01 |
2012-06-07 |
キッコーマン株式会社 |
大腸菌形質転換体、それを用いたフラビン結合型グルコースデヒドロゲナーゼの製造方法、および、変異型フラビン結合型グルコースデヒドロゲナーゼ
|
|
TWI530489B
(zh)
*
|
2011-03-22 |
2016-04-21 |
必治妥美雅史谷比公司 |
雙（氟烷基）－１，４－苯二氮呯酮化合物
|
|
EP2721070A1
(en)
|
2011-06-17 |
2014-04-23 |
Harris, Adrian, L. |
Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
|
|
TWI583699B
(zh)
*
|
2011-09-23 |
2017-05-21 |
安可美德藥物股份有限公司 |
Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
|
|
RU2014122048A
(ru)
*
|
2011-11-16 |
2015-12-27 |
Онкомед Фармасьютикалс, Инк. |
Мутации рецептора notch человека и их применение
|
|
AU2013214172A1
(en)
|
2012-02-03 |
2014-08-14 |
Medimmune Limited |
Process for reducing antibody aggregate levels and antibodies produced thereby
|
|
US9856320B2
(en)
*
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
WO2013173542A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating cancer with notch2/3 antibodies
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
JP2015520172A
(ja)
|
2012-05-31 |
2015-07-16 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｄｌｌ−４に結合する抗原結合蛋白質
|
|
KR101535341B1
(ko)
|
2012-07-02 |
2015-07-13 |
한화케미칼 주식회사 |
Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
|
|
SI3495387T1
(sl)
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
|
|
WO2014049100A1
(en)
|
2012-09-28 |
2014-04-03 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
CA2889638A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑治療卵巢癌之方法
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
WO2015130751A1
(en)
|
2014-02-26 |
2015-09-03 |
Medimmune, Llc |
Methods of treatment with dll4 antagonists
|
|
AU2015229591B2
(en)
*
|
2014-03-11 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-EGFRvlll antibodies and uses thereof
|
|
EP3166627A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Notch pathway inhibition
|
|
EP3212233B1
(en)
|
2014-10-31 |
2020-06-24 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
US11339213B2
(en)
*
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
WO2020012447A1
(en)
|
2018-07-13 |
2020-01-16 |
Composite Interceptive Med-Science Laboratories Private Limited |
Polyherbal formulation and method for production thereof
|